Nadolol (versus unexposed) - Medication and Pregnancy KB

Nadolol (versus unexposed)

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Albertini 2023	Canada 2012 - 2021 retrospective cohort	The tertiary Pregnancy and Heart Disease Program at the University of Toronto, Canada.	Babies born to mothers with long QT syndrome who had taken Nadolol during pregnancy.	unexposed, sick Babies born to mothers with long QT syndrome who had not taken beta-blockers during pregnancy.	during pregnancy (anytime or not specified)	5 / 7
Albertini 2023	Canada 2012 - 2021 retrospective cohort		Maternal clinical history including medications was collected (no other details).		during pregnancy (anytime or not specified)	5 / 7
Delteil 2024	France 2004 - 2021 retrospective cohort (claims database)	EFEMERIS (Évaluation chez la Femme Enceinte des MÉdicaments et de leurs RISques) database, and the Registre des Handicaps de l'Enfant en Haute-Garonne (RHE31), Haute-Garonne, France.	Pregnancies with at least one dispensed prescription of Nadolol during pregnancy (between last menstrual period and delivery).	unexposed (general population or NOS) Pregnancies without dispensed prescription of beta-blockers and other anti-hypertensive agents during pregnancy.	at least 1st trimester	14 / 172284	When available, data in women with chronic pathology (hypertension or cardiac), treated at least during the 1st trimester were preferred to all indications (including gestational hypertension, ...). Exposure at least T1 considered as chronic indications.
Delteil 2024	France 2004 - 2021 retrospective cohort (claims database)		Women's drug exposure during pregnancy was estimated on the basis of dispensed prescription drugs recorded by the French Assurance Maladie.		at least 1st trimester	14 / 172284

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol